<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/0235-2990-2026-71-5-6-5-12</article-id><article-id custom-type="edn" pub-id-type="custom">TVJWOO</article-id><article-id custom-type="elpub" pub-id-type="custom">antibiotics-1401</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Способность базидиомицетов Cyclocybe cylindracea, Hericium erinaceus, Stropharia rugosoannulata и Hypsizygus ulmarius к образованию ингибиторов биосинтеза стеролов</article-title><trans-title-group xml:lang="en"><trans-title>The Ability of Basidiomycetes Cyclocybe cylindracea, Hericium erinaceus, Stropharia rugosoannulata, and Hypsizygus ulmarius to Produce Sterol Biosynthesis Inhibitors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2293-6646</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тренин</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Trenin</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тренин Алексей Сергеевич — д. б. н., ведущий научный сотрудник, заведующий лабораторией Разработки методов поиска биологически активных соединений</p><p>AuthorID: 84742 </p><p>Москва</p></bio><bio xml:lang="en"><p>Alexey S. Trenin — D. Sc. in Biology, Leading Researcher, Head of the Laboratory for the Development of Methods for Bioactive Compounds Discovery</p><p>Moscow</p></bio><email xlink:type="simple">as-trenin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-9913-2962</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цвигун</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsvigun</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цвигун Елена Анатольевна — инженер лаборатории Разработки методов поиска биологически активных соединений </p><p>Москва</p></bio><bio xml:lang="en"><p>Elena A. Tsvigun — Engineer at the Laboratory of Development of Methods for Searching for Biologically Active Compounds</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3773-250X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maximova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максимова Мария Андреевна — инженер лаборатории Разработки методов поиска биологически активных соединений </p><p>Москва</p></bio><bio xml:lang="en"><p>Maria A. Maximova — Engineer at the Laboratory of Development of Methods for Searching for Biologically Active Compounds</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2213-8767</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Леонтьева</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Leonteva</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Леонтьева Мария Ильинична — инженер лаборатории биосинтеза биологически активных веществ</p><p>Москва</p></bio><bio xml:lang="en"><p>Maria I. Leonteva [Shuktueva] — Engineer at the Laboratory of Biosynthesis of Biologically Active Substances</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0391-0339</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Краснопольская</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasnopolskaya</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Краснопольская Лариса Михайловна — д. б. н., ведущий научный сотрудник, заведующая лабораторией Биосинтеза биологически активных веществ</p><p>Москва</p></bio><bio xml:lang="en"><p>Larissa M. Krasnopolskaya — D. Sc. in Biology, Leading Researcher, Head of the Laboratory of Biosynthesis of Biologically Active Substances</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт по изысканию новых антибиотиков им. Г. Ф. Гаузе» (ФГБНУ НИИНА)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Gause Institute of New Antibiotics</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2026</year></pub-date><volume>71</volume><issue>5-6</issue><fpage>5</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; ООО «Издательство ОКИ», 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">ООО «Издательство ОКИ»</copyright-holder><copyright-holder xml:lang="en">ООО «Издательство ОКИ»</copyright-holder><license xlink:href="https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/1401">https://www.antibiotics-chemotherapy.ru/jour/article/view/1401</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Лечение инфекционных, опухолевых и сердечно-сосудистых заболеваний по-прежнему остаётся важнейшей задачей современной медицины. Поиск биологически активных вторичных метаболитов позволяет выявлять природные соединения, способные стать основой для разработки принципиально новых лекарственных средств. Применение оригинальных методов поиска, вовлечение в поиск новых групп организмов, включая базидиомицеты, могут способствовать значительному повышению эффективности поисковых работ и, в конечном счёте, привести к созданию новых более действенных лекарственных препаратов.</p></sec><sec><title>Цель</title><p>Цель. Выявление способности базидиомицетов к образованию ингибиторов биосинтеза стеролов (ИБС), а также метаболитов, обладающих антимикробными свойствами.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Выращивание базидиомицетов проводили методом погружённого культивирования. Биологически активные соединения получали экстракцией этилацетатом из культуральной жидкости и этанолом из мицелия продуцентов. Оценку антибактериальной и антифунгальной активности экстрактов с определением минимальной подавляющей концентрации проводили методом серийных разведений в жидкой питательной среде, а также методом диффузии в агар. Для выявления ИБС применяли тест-систему с использованием микробной культуры Halobacterium salinarum, обладающей мевалонатным путём биосинтеза стеролов.</p></sec><sec><title>Результаты</title><p>Результаты. Штаммы базидиомицетов, относящихся к видам Cyclocybe cylindracea, Hericium erinaceus, Stropharia rugosoannulata и Hypsizygus ulmarius, выращенные путём погружённого культивирования, показали наличие антибактериальной и антифунгальной активности. Изученные штаммы C. cylindracea, S. rugosoannulata и H. ulmarius показали себя в микробной системе H. salinarum как возможные продуценты ИБС. У штаммов C. cylindracea и H. ulmarius выявлена способность к образованию ингибиторов ранних (до образования мевалоната) этапов биосинтеза стеролов.</p></sec><sec><title>Заключение</title><p>Заключение. Среди 4 изученных штаммов базидиомицетов 3 штамма — C. cylindracea, S. rugosoannulata и H. ulmarius выявлены как возможные продуценты ИБС. Штаммы C. cylindracea и H. ulmarius показали способность к образованию ингибиторов ранних этапов биосинтеза стеролов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Treatment of infectious, tumor, and cardiovascular diseases remains the most important task of modern medicine. The search for biologically active secondary metabolites allows us to detect natural compounds that can serve as the basis for the development of fundamentally new drugs. The use of original search methods and the involvement of new groups of organisms, including basidiomycetes, can significantly increase the efficiency of screening work and, ultimately, lead to the development of new, more effective drugs.</p><p>The aim of the work was to reveal the ability of Basidiomycetes to produce sterol biosynthesis inhibitors (SBIs) and metabolites with antimicrobial properties.</p></sec><sec><title>Material and methods</title><p>Material and methods. Basidiomycetes were grown using the submerged cultivation method. Biologically active compounds were obtained by extraction with ethyl acetate from the culture broth and with ethanol from the mycelium of the producers. The antibacterial and antifungal activity of the extracts with determination of the minimum inhibitory concentration was assessed using the serial dilution method in liquid media, as well as the agar diffusion assay. To detect SBIs, a test system with Halobacterium salinarum microbial culture, which possesses the mevalonate pathway of sterol biosynthesis, was used.</p></sec><sec><title>Results</title><p>Results. Basidiomycete strains belonging to the species Cyclocybe cylindracea, Hericium erinaceus, Stropharia rugosoannulata and Hypsizygus ulmarius grown by submerged cultivation showed antibacterial and antifungal activity. In the microbial system of H. salinarum, the studied strains of C. cylindracea, S. rugosoannulata and H. ulmarius showed themselves as possible producers of SBIs. The strains C. cylindracea and H. ulmarius revealed the ability to form inhibitors of the early stages of sterol biosynthesis before the mevalonate formation.</p></sec><sec><title>Conclusion</title><p>Conclusion. Among the 4 studied basidiomycete strains, 3 strains — C. cylindracea, S. rugosoannulata, and H. ulmarius — were identified as potential producers of SBIs. C. cylindracea and H. ulmarius strains demonstrated the ability to produce inhibitors of the early stages of sterol biosynthesis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>базидиомицеты</kwd><kwd>ингибиторы биосинтеза стеролов</kwd><kwd>экстракты культуральной жидкости и мицелия</kwd><kwd>антимикробная активность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>basidiomycetes</kwd><kwd>sterol biosynthesis inhibitors</kwd><kwd>culture broth and mycelium extracts</kwd><kwd>antimicrobial activity</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки.</funding-statement><funding-statement xml:lang="en">The study had no sponsorship.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Тренин А.С. Микробные метаболиты — ингибиторы биосинтеза стеролов, их химическое разнообразие и особенности механизма действия. Биоорганическая химия. 2013; 39 (6): 633–657. doi: https://doi.org/10.1134/S1068162013060095</mixed-citation><mixed-citation xml:lang="en">Trenin AS. Microbial metabolites inhibiting sterol biosynthesis: Their chemical diversity and characteristics of the mechanism of action. Russian Journal of Bioorganic Chemistry. 2013; 39 (6): 565–587. (In Russ.). doi: https://doi.org/10.1134/S1068162013060095.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sadowska A, Osiński P, Roztocka A, Kaczmarz-Chojnacka K, Zapora E, Sawicka D, Car H. Statins-From Fungi to Pharmacy. Review. Int J Mol Sci. 2023 Dec 29; 25 (1): 466. doi: 10.3390/ijms25010466.</mixed-citation><mixed-citation xml:lang="en">Sadowska A, Osiński P, Roztocka A, Kaczmarz-Chojnacka K, Zapora E, Sawicka D, Car H. Statins-From Fungi to Pharmacy. Review. Int J Mol Sci. 2023 Dec 29; 25 (1): 466. doi: 10.3390/ijms25010466.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Marahatha R, Basnet S, Bhattarai BR, Budhathoki P, Aryal B, Adhikari B, et al. Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis. BMC Complement Med Ther. 2021 Jan 1; 21 (1): 1. doi: 10.1186/s12906-020-03162-5.</mixed-citation><mixed-citation xml:lang="en">Marahatha R, Basnet S, Bhattarai BR, Budhathoki P, Aryal B, Adhikari B, et al. Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis. BMC Complement Med Ther. 2021 Jan 1; 21 (1): 1. doi: 10.1186/s12906-020-03162-5.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu T, Chen X, Li C, Tu J, Liu N, Xu D, Sheng C. Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections. Eur J Med Chem. 2021; Oct 5; 221: 113524. doi: 10.1016/j.ejmech.2021.113524.</mixed-citation><mixed-citation xml:lang="en">Zhu T, Chen X, Li C, Tu J, Liu N, Xu D, Sheng C. Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections. Eur J Med Chem. 2021; Oct 5; 221: 113524. doi: 10.1016/j.ejmech.2021.113524.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang R, Wang Y, Wu A, Wang J, Zhang J. Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges. Eur J Med Chem. 2023 Nov 5; 259: 115658. doi: 10.1016/j.ejmech.2023.115658.</mixed-citation><mixed-citation xml:lang="en">Zhang R, Wang Y, Wu A, Wang J, Zhang J. Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges. Eur J Med Chem. 2023 Nov 5; 259: 115658. doi: 10.1016/j.ejmech.2023.115658.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Song L, Wang S, Zou H, Yi X, Jia S, Li R, Song J. Regulation of ergosterol biosynthesis in pathogenic fungi: opportunities for therapeutic development. Microorganisms. 2025 Apr 10; 13 (4): 862. doi: 10.3390/microorganisms13040862.</mixed-citation><mixed-citation xml:lang="en">Song L, Wang S, Zou H, Yi X, Jia S, Li R, Song J. Regulation of ergosterol biosynthesis in pathogenic fungi: opportunities for therapeutic development. Microorganisms. 2025 Apr 10; 13 (4): 862. doi: 10.3390/microorganisms13040862.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Nes WD, Chaudhuri M, Leaver DJ. Druggable sterol metabolizing enzymes in infectious diseases: cell targets to therapeutic leads. Biomolecules. 2024; 14 (3): 249. doi: 10.3390/biom14030249.</mixed-citation><mixed-citation xml:lang="en">Nes WD, Chaudhuri M, Leaver DJ. Druggable sterol metabolizing enzymes in infectious diseases: cell targets to therapeutic leads. Biomolecules. 2024; 14 (3): 249. doi: 10.3390/biom14030249.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kamel EM, Abdelrheem DA, Salah B, Lamsabhi AM. Phytochemical inhibitors of squalene epoxidase: Integrated In silico and In vitro mechanistic insights for targeting cholesterol biosynthesis. Arch Biochem Biophys. 2025 Jun; 768: 110372. doi: 10.1016/j.abb.2025.110372.</mixed-citation><mixed-citation xml:lang="en">Kamel EM, Abdelrheem DA, Salah B, Lamsabhi AM. Phytochemical inhibitors of squalene epoxidase: Integrated In silico and In vitro mechanistic insights for targeting cholesterol biosynthesis. Arch Biochem Biophys. 2025 Jun; 768: 110372. doi: 10.1016/j.abb.2025.110372.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Allam AA, Rudayni HA, Ahmed NA, Aba Alkhayl FF, Lamsabhi AM, Kamel EM. Multidimensional insights into squalene epoxidase drug development: in vitro mechanisms, in silico modeling, and in vivo implications. Expert Opin Ther Targets. 2025 Jun; 29 (6): 385–403. doi: 10.1080/14728222.2025.2500420.</mixed-citation><mixed-citation xml:lang="en">Allam AA, Rudayni HA, Ahmed NA, Aba Alkhayl FF, Lamsabhi AM, Kamel EM. Multidimensional insights into squalene epoxidase drug development: in vitro mechanisms, in silico modeling, and in vivo implications. Expert Opin Ther Targets. 2025 Jun; 29 (6): 385–403. doi: 10.1080/14728222.2025.2500420.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Göbel A, Rauner M, Hofbauer LC, Rachner TD. Cholesterol and beyond — the role of the mevalonate pathway in cancer biology. Review. Biochim Biophys Acta Rev Cancer. 2020 Apr; 1873 (2): 188351. doi: 10.1016/j.bbcan.2020.188351.</mixed-citation><mixed-citation xml:lang="en">Göbel A, Rauner M, Hofbauer LC, Rachner TD. Cholesterol and beyond — the role of the mevalonate pathway in cancer biology. Review. Biochim Biophys Acta Rev Cancer. 2020 Apr; 1873 (2): 188351. doi: 10.1016/j.bbcan.2020.188351.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Laka K, Makgoo L, Mbita Z. Cholesterol-lowering phytochemicals: targeting the mevalonate pathway for anticancer interventions. Front Genet. 2022 Mar 22; 13: 841639. doi: 10.3389/fgene.2022.841639.</mixed-citation><mixed-citation xml:lang="en">Laka K, Makgoo L, Mbita Z. Cholesterol-lowering phytochemicals: targeting the mevalonate pathway for anticancer interventions. Front Genet. 2022 Mar 22; 13: 841639. doi: 10.3389/fgene.2022.841639.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021 Jul 24; 40 (1): 241. doi: 10.1186/s13046-021-02041-2.</mixed-citation><mixed-citation xml:lang="en">Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021 Jul 24; 40 (1): 241. doi: 10.1186/s13046-021-02041-2.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Q, Dong J, Yu Z. Pleiotropic use of Statins as non lipid lowering drugs. Int J Biol Sci. 2020; 16 (14): 2704–2711. doi: 10.7150/ijbs.42965.</mixed-citation><mixed-citation xml:lang="en">Zhang Q, Dong J, Yu Z. Pleiotropic use of Statins as non lipid lowering drugs. Int J Biol Sci. 2020; 16 (14): 2704–2711. doi: 10.7150/ijbs.42965.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Visbal G, Navarro M. Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer? Review. Expert Opin Drug Discov. 2025 Aug; 20 (8): 1031–1044. doi: 10.1080/17460441.2025.2530589.</mixed-citation><mixed-citation xml:lang="en">Visbal G, Navarro M. Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer? Review. Expert Opin Drug Discov. 2025 Aug; 20 (8): 1031–1044. doi: 10.1080/17460441.2025.2530589.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Boruta T, Bizukojc M. Production of lovastatin and itaconic acid by Aspergillus terreus: a comparative perspective. World J Microbiol Biotechnol. 2017 Feb; 33 (2): 34. doi: 10.1007/s11274-017-2206-9.</mixed-citation><mixed-citation xml:lang="en">Boruta T, Bizukojc M. Production of lovastatin and itaconic acid by Aspergillus terreus: a comparative perspective. World J Microbiol Biotechnol. 2017 Feb; 33 (2): 34. doi: 10.1007/s11274-017-2206-9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Тренин А.С. Микробная тест-система для поиска ингибиторов биосинтеза стеролов. Антибиотики и химиотер. 2013; 58 (3–4): 3–9.</mixed-citation><mixed-citation xml:lang="en">Trenin AS. Microbial test-system for screening of inhibitors of sterol biosynthesis. Antibiot Khimioter = Antibiotics and Chemotherapy. 2013; 58 (3–4): 3–9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Тренин А.С. Микробные модели в поиске ингибиторов биосинтеза стеролов. Антибиотики и химиотер. 2013; 58 (7–8): 3–14.</mixed-citation><mixed-citation xml:lang="en">Trenin AS. Microbial models in screening of inhibitors of sterol biosynthesis. Antibiot Khimioter = Antibiotics and Chemotherapy. 2013; 58 (7–8): 3–14. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Atli B, Yamac M. Screening of medicinal higher Basidiomycetes mushrooms from Turkey for lovastatin production. Int J Med Mushrooms. 2012; 14 (2): 149–159. doi: 10.1615/intjmedmushr.v14.i2.30.</mixed-citation><mixed-citation xml:lang="en">Atli B, Yamac M. Screening of medicinal higher Basidiomycetes mushrooms from Turkey for lovastatin production. Int J Med Mushrooms. 2012; 14 (2): 149–159. doi: 10.1615/intjmedmushr.v14.i2.30.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Автономова А.В., Краснопольская Л.М. Противоопухолевые и иммуномодулирующие свойства трутовика лакированного (Ganoderma lucidum). Микология и фитопатология. 2013; 47 (1): 3–11.</mixed-citation><mixed-citation xml:lang="en">Avtonomova AV, Krasnopolskaya LM. Anti-tumor and immunomodulatory activities of Ganoderma lucidum. Mycology and Phytopathology. 2013; 47 (1): 3–11. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bills GF, Gloer JB. Biologically Active Secondary Metabolites from the Fungi. Microbiol Spectr. 2016 Nov; 4 (6). doi: 10.1128/microbiolspec. FUNK-0009-2016.</mixed-citation><mixed-citation xml:lang="en">Bills GF, Gloer JB. Biologically Active Secondary Metabolites from the Fungi. Microbiol Spectr. 2016 Nov; 4 (6). doi: 10.1128/microbiolspec. FUNK-0009-2016.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bhambri A, Srivastava M, Mahale VG, Mahale S, Karn SK. Mushrooms as potential sources of active metabolites and medicines. Front Microbiol. 2022 Apr 26; 13: 837266. doi: 10.3389/fmicb.2022.837266.</mixed-citation><mixed-citation xml:lang="en">Bhambri A, Srivastava M, Mahale VG, Mahale S, Karn SK. Mushrooms as potential sources of active metabolites and medicines. Front Microbiol. 2022 Apr 26; 13: 837266. doi: 10.3389/fmicb.2022.837266.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Schrey H, Lambert C, Stadler M. Fungi: pioneers of chemical creativity — techniques and strategies to uncover fungal chemistry. IMA Fungus. 2025 Mar 7; 16: e142462. doi: 10.3897/imafungus.16.142462.</mixed-citation><mixed-citation xml:lang="en">Schrey H, Lambert C, Stadler M. Fungi: pioneers of chemical creativity  — techniques and strategies to uncover fungal chemistry. IMA Fungus. 2025 Mar 7; 16: e142462. doi: 10.3897/imafungus.16.142462.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lysakova V., Krasnopolskaya L., Yarina M., Ziangirova M. Antibacterial and antifungal activity of metabolites from Basidiomycetes: a review. Antibiotics (Basel). 2024; 13 (1026). doi: doi.org/10.3390/antibiotics13111026.</mixed-citation><mixed-citation xml:lang="en">Lysakova V., Krasnopolskaya L., Yarina M., Ziangirova M. Antibacterial and antifungal activity of metabolites from Basidiomycetes: a review. Antibiotics (Basel). 2024; 13 (1026). doi: doi.org/10.3390/antibiotics13111026.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Pandey VV, Varshney VK, Pandey A. Lovastatin: a journey from ascomycetes to Basidiomycetes fungi. Journal of Biologically Active Products from Nature. 2019; 9 (3): 162–178. doi: 10.1080/22311866.2019.1622452.</mixed-citation><mixed-citation xml:lang="en">Pandey VV, Varshney VK, Pandey A. Lovastatin: a journey from ascomycetes to Basidiomycetes fungi. Journal of Biologically Active Products from Nature. 2019; 9 (3): 162–178. doi: 10.1080/22311866.2019.1622452.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Abidin MHZ, Abdullah N, Abidin NZ. Therapeutic properties of Pleurotus species (Oyster mushrooms) for atherosclerosis: a review. International Journal of Food Properties. 2017; 20 (6): 1251–1261. doi: 10.1080/10942912.2016.1210162</mixed-citation><mixed-citation xml:lang="en">Abidin MHZ, Abdullah N, Abidin NZ. Therapeutic properties of Pleurotus species (Oyster mushrooms) for atherosclerosis: a review. International Journal of Food Properties. 2017; 20 (6): 1251–1261. doi: 10.1080/10942912.2016.1210162</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Краснопольская Л.М., Тренин А.С., Бычкова О.П., Цвигун Е.А., Джавахян Б.Р. Погруженная культура Pleurotus eryngii: антибиотические свойства и способность к образованию ингибиторов биосинтеза стеролов. Universum: химия и биология. 2015; 11 (18): 4.</mixed-citation><mixed-citation xml:lang="en">Krasnopolskaya LM, Trenin AS, Bychkova OP, Tsvigun EA, Dzhavakhyan BR. Submerged culture of Pleurotus eryngii: antibiotic activities and ability to produce the inhibitors of sterol biosynthesis. Universum: Khimiya i Biologiya. 2015; 11 (18): 4. (In Russ..</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Тренин А.С. Микробная модель Halobacterium salinarum для поиска ингибиторов биосинтеза стеролов. Антибиотики и химиотер. 2013; 58 (5–6): 3–10.</mixed-citation><mixed-citation xml:lang="en">Trenin AS. Microbial model of Halobacterium salinarum for screening inhibitors of sterol biosynthesis. Antibiot Khimioter = Antibiotics and Chemotherapy. 2013; 58 (5–6): 3–10. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Soppa J. From genomes to function: Haloarchaea as model organisms. Microbiology. 2006; 152 (Pt 3): 585–590. doi: 10.1099/mic.0.28504-0.</mixed-citation><mixed-citation xml:lang="en">Soppa J. From genomes to function: Haloarchaea as model organisms. Microbiology. 2006; 152 (Pt 3): 585–590. doi: 10.1099/mic.0.28504-0.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Альмяшева Н.Р., Ярина М.С., Голышкин А.В., Джавахян Б.Р., Краснопольская Л.М. Антиоксидантные свойства водорастворимых полисахаридов и этанольных экстрактов мицелия ксилотрофных базидиальных грибов. Антибиотики и химиотер. 2017; 62 (7–8): 8–12.</mixed-citation><mixed-citation xml:lang="en">Almyasheva NR, Yarina MS, Golyshkin AV, Dzhavakhyan BR, Krasnopolskaya LM. Antioxidant properties of water-soluble polysaccharides and ethanolic extracts of xylotrophic basidiomycetes mycelium. Antibiot Khimioter = Antibiotics and Chemotherapy. 2017; 62 (7–8): 8–12. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing. 35th ed. Wayne, PA: CLSI; 2025. [cited 2025 Jan 27]. Available from: https://clsi.org/standards/products/microbiology/documents/m100/</mixed-citation><mixed-citation xml:lang="en">CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing. 35th ed. Wayne, PA: CLSI; 2025. [cited 2025 Jan 27]. Available from: https://clsi.org/standards/products/microbiology/documents/m100/</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">CLSI M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute. Pensylvania, 2013.</mixed-citation><mixed-citation xml:lang="en">CLSI M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute. Pensylvania, 2013.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">CLSI M38-A2. Ed. 2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standart. Clinical and Laboratory Standards Institute. Pensylvania, 2008.</mixed-citation><mixed-citation xml:lang="en">CLSI M38-A2. Ed. 2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standart. Clinical and Laboratory Standards Institute. Pensylvania, 2008.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Кубанова А.А., Степанова Ж.В., Гуськова Т.А., Пушкина Т.В., Крылова Л.Ю., Шилова И.Б., Тренин А.С. Методические указания по изучению противогрибковой активности фармакологических веществ. В кн.: Руководство по проведению доклинических исследований лекарственных средств. Часть первая. Под ред. А. Н. Миронова. М.: Гриф и К, 2012; 944: 576–584.</mixed-citation><mixed-citation xml:lang="en">Kubanova AA, Stepanova ZV, Guskova TA, Pushkina TV, Krylova LYu, Shilova IB, Trenin AS. Metodicheskie ukazaniya po izucheniyu protivogribkovoi aktivnosti farmakologicheskikh veshchestv. In book: Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv. Part 1. AN Mironov (ed.). Moscow: Grif and Co., 2012; (1): 576–584. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Тренин А. С., Цвигун Е. А., Максимова М. А., Леонтьева М. И., Автономова А. В., Краснопольская Л. М. Базидиальные грибы Ganoderma lucidum, Kuehneromyces mutabilis, Flammulina velutipes, Pleurotus ostreatus и Lentinula edodes, как возможные продуценты ингибиторов биосинтеза стеролов. Антибиотики и химиотер. 2026; 71 (1–2): 4–11. doi: https://doi.org/10.37489/0235-2990-2026-71-1-2-4-11. EDN: QEVTWA.</mixed-citation><mixed-citation xml:lang="en">Trenin AS, Tsvigun EA, Maximova MA, Leonteva MI, Avtonomova AV, Krasnopolskaya LM. Basidiomycetes Ganoderma lucidum, Kuehneromyces mutabilis, Flammulina velutipes, Pleurotus ostreatus and Lentinula edodes as possible producers of sterol biosynthesis inhibitors. Antibiot Khimioter = Antibiotics and Chemotherapy. 2026; 71 (1–2): 4–11. (In Russ.). doi: https://doi.org/10.37489/0235-2990-2026-71-1-2-4-11. EDN: QEVTWA.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
